Ch.1: Defining the Problem.- Ch.2: Prostate Cancer Screening: Navigating the Controversy.- Ch.3: Is the PSA Era Over?.- Ch.4: PSA Dynamics.- Ch.5: Percent Free PSA.- Ch.6: PCA3 and other Urinary Markers.- Ch.7: Blood-Based Tumor Markers for Prostate Cancer.- Ch.8: Prediction Models in Prostate Cancer Diagnosis and Preparation for Biopsy.- Ch.9: Is There a Role for Medications to Reduce the Need for Prostate Biopsy?.- Ch.10: Indications For Initial Biopsy:  Is The PSA Threshold Over?.- Ch.11: Preparation for Prostate Biopsy.- Ch.12: Pain Prevention.- Ch.13: Prostate Biopsy.- Ch.14: Prostate Biopsy Techniques.- Ch.15: Transperineal Biopsy.- Ch.16: Pathological Implications of Prostate Biopsy.- Ch.17: Complications of Transrectal Ultrasound Guided Prostate Biopsy.- Ch.18: After the Biopsy: Management of High Grade Prostatic Intraepithelial Neoplasia (HGPIN).- Ch.19: Atypical Small Acinar Proliferation.- Ch.20: Repeat Prostate Biopsy Strategies – Indications and Techniques.- Ch.21: Transperineal Mapping Biopsy of the Prostate for Assessment of the Minimal Risk Patient.- Ch.22: Management of the Patient Following a Negative Biopsy: Saturation Biopsy.- Ch.23: Role of imaging as an adjunct or replacement for biopsy: American Experience.- Ch.24: Role Of Imaging As An Adjunct Or Replacement For Biopsy: European Experience.- Ch.25: Prostate Cancer Detection: Lessons Learnt in the Cleveland Clinic Experience with Focus on the Negative Biopsy.- Ch.26: Future Directions in Prostate Cancer Diagnosis.